To provide an income greater than that of the FTSE All Share Index together with capital growth over the longer term.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 6.0% |
AstraZeneca | 4.4% |
BP | 4.3% |
Vodafone | 4.3% |
Royal Dutch Shell | 4.2% |
Imperial Tobacco | 4.0% |
Indus Gas | 3.8% |
KSK Power Ventur | 3.8% |
Compass Group | 3.4% |
Reed Elsevier | 3.4% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 6.0% |
AstraZeneca | 4.4% |
BP | 4.3% |
Vodafone | 4.3% |
Other | 81% |
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 01/01/1963 |
---|---|
Fund Manager | Richard Dunbar |
TER | 1.63 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | 1000 |
Additional | n/a |
Savings | 50 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research